[ MULTIMEDIA ] [ MULTIMEDIA ] [ MULTIMEDIA ] [ MULTIMEDIA ] 1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is indicated for procedures requiring a rapid and short - acting topical ophthalmic anesthetic .
Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is an ester local anesthetic indicated for procedures requiring a rapid and short - acting topical ophthalmic anesthetic .
( 1 ) 2 DOSAGE AND ADMINISTRATION One drop topically in the eye ( s ) as needed .
Discard unused portion .
( 2 . 1 ) 2 . 1 Topical Administration One drop topically in the eye as needed .
Discard unused portion .
2 . 2 Sterile Field Administration Open package using standard aseptic technique .
The DROP ‑ TAINER ® dispenser may then be allowed to fall upon a sterile surface .
The entire outer surface of the DROP ‑ TAINER ® dispenser and its contents are sterile .
3 DOSAGE FORMS AND STRENGTHS Sterile ophthalmic solution containing 0 . 5 % w / v tetracaine hydrochloride equivalent to tetracaine 0 . 44 % w / v .
Sterile ophthalmic solution containing 0 . 5 % tetracaine hydrochloride ( 3 ) 4 CONTRAINDICATIONS SECTION None .
None ( 4 ) Warnings and Precautions ( 5 . 4 ) 2 / 2022 5 WARNINGS AND PRECAUTIONS • Do not use intracamerally since use may damage corneal endothelial cells ( 5 . 1 ) • Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage .
( 5 . 2 ) • Patients should not touch the eye for at least 10 - 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye .
( 5 . 3 ) • For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is not intended for patient self - administration .
( 5 . 4 ) 5 . 1 Corneal injury with Intracameral Use Not for injection or intraocular use .
Do not use intracamerally because use of TetracaineHydrochloride Ophthalmic Solution 0 . 5 % may lead to damage of the corneal endothelial cells .
5 . 2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage .
5 . 3 Corneal Injury due to Insensitivity Patients should not touch the eye for at least 10 - 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye .
5 . 4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is indicated for administration under the direct supervision of a healthcare provider .
Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is not intended for patient self - administration [ see Warnings and Precautions ( 5 . 2 ) ] .
6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling : • Corneal injury with Intracameral Use [ See Warnings and Precautions ( 5 . 1 ) ] • Corneal Toxicity [ See Warnings and Precautions ( 5 . 2 ) ] • Corneal Injury due to Insensitivity [ See Warnings and Precautions ( 5 . 3 ) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % .
Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .
Ocular Adverse Reactions Transient stinging , burning , and conjunctival redness , eye irritation , eye pain , ocular discomfort .
Ocular adverse events : stinging , burning , conjunctival redness ( 6 ) To report SUSPECTED ADVERSE REACTIONS , contact Alcon Laboratories , Inc . , at 1 - 800 - 757 - 9195 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch .
8 USE IN SPECIFIC POPULATIONS 8 . 1 Pregnancy Risk Summary There are no adequate and well - controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % in pregnant women .
Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature .
8 . 2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % is excreted in human milk or to assess its effects on milk production / excretion .
The developmental and health benefits of breastfeeding should be considered along with the mother ’ s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % or from the underlying maternal condition .
8 . 3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % on fertility are available .
8 . 4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials .
Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population .
8 . 5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients .
10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including TetracaineHydrochloride Ophthalmic Solution 0 . 5 % may produce permanent corneal opacification and ulceration with accompanying visual loss .
Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems .
11 DESCRIPTION Tetracaine hydrochloride is chemically designated as benzoic acid , 4 - ( butylamino ) - , 2 - ( dimethylamino ) ethyl ester , monohydrochloride .
Its chemical formula is C15H24N2O2 • HCl and it is represented by the chemical structure : [ MULTIMEDIA ] Tetracaine hydrochloride is a fine , white , crystalline , odorless powder and has a molecular weight of 300 . 82 .
Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % has a pH of 3 . 7 to 5 . 5 .
Active ingredient : tetracaine hydrochloride 0 . 5 % w / v ( equivalent to 0 . 44 % w / v tetracaine ) Inactive ingredients : sodium chloride , sodium acetate trihydrate , acetic acid ( to adjust pH approximately 4 . 5 ) , Water for Injection , USP 12 CLINICAL PHARMACOLOGY 12 . 1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia .
12 . 3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % has not been studied .
Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues .
13 NONCLINICAL TOXICOLOGY 13 . 1 Carcinogenesis , Mutagenesis , Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature .
Long - term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride .
Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature .
14 CLINICAL STUDIES Topical administration of tetracainehydrochloride ophthalmic solution results in localized temporary anesthesia .
The maximum effect is achieved within 10 – 20 seconds after instillation , with efficacy lasting 10 – 20 minutes .
Duration of effect can be extended with repeated dosing .
[ see Corneal toxicity ( 5 . 2 ) and Overdosage ( 10 ) ] .
16 HOW SUPPLIED / STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution 0 . 5 % STERI - UNITS ® is supplied as single patient use , 4 mL filled in 4 - mL natural medium - or low - density polyethylene plastic DROP - TAINER ® dispensers and natural low - density polyethylene tips with white polypropylene caps in a carton of 12 .
Each sterilized DROP - TAINER ® dispenser is packaged in a clear PVC and Tyvek blister .
This product does not contain a preservative ; discard unused portion .
NDC 0065 - 0741 - 14 Storage : Store at 2 ° C to 25 ° C ( 36 ° F to 77 ° F ) .
Protect from light .
Do not use if solution contains crystals , is cloudy , or discolored .
17 PATIENT COUNSELING INFORMATION Eye Care Precaution Advise patients that , due to the effect of the anesthetic , their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries .
ALCON ® Distributed by : ALCON LABORATORIES , INC .
Fort Worth , Texas 76134 USA © 2021 Alcon Inc .
300055204 - 1121 PRINCIPAL DISPLAY PANEL NDC 0065 - 0741 - 14 Tetracaine Hydrochloride Ophthalmic Solution , 0 . 5 % STERi - UNITS Single Dose DROP - TAINER ® dispensers for topical use . See package insert for directions .
Rx Only 12 x 4 mL STERILE Alcon Alcon Laboratories , Inc .
Fort Worth , Texas 76134 USA Printed in USA NDC 0065 - 0741 - 14 TETRACAINE HYDROCHLORIDE Ophthalmic Solution 0 . 5 % INGREDIENTS : Each mL contains : Active : Tetracaine Hydrochloride 0 . 5 % .
( equivalent to tetracaine ( 0 . 44 % ) Inactive : Sodium Chloride , Sodium Acetate Trihydrate , Acetic Acid ( to adjust pH ) , Water for Injection .
USUAL DOSAGE : One drop topically in the eye ( s ) as needed .
Discard unused portion .
STORAGE : Store at 2 ° C to 25 ° C ( 36 ° F to 77 ° F ) .
Protect from Light .
Do not use if discolored Printed in USA [ MULTIMEDIA ] NDC 0065 - 0741 - 14 TETRACAINE HYDROCHLORIDE Ophthalmic Solution 0 . 5 % 4 mL Rx Only SINGLE DOSE UNIT – DISCARD UNUSED PORTION H14660 - 0916 LOT : EXP : [ MULTIMEDIA ] TETRACAINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0 . 5 % 4 mL STERILE UNTIL OPENED PROTECT FROM LIGHT Rx Only NDC 0065 - 0741 - 14 9013226 - 0416 Alcon Laboratories , Inc .
Fort Worth , Texas 76134 USA Alcon ® © 2016 Novartis LOT : EXP . : [ MULTIMEDIA ]
